NEDD4L and central nervous system cancer: In addition, Kaplan-Meier analysis showed that patients with NEDD4L-low-expressing glioma exhibit a worse prognosis compared with patients with NEDD4L-high-expressing glioma (Figure 2(c) right panel), which demonstrates the potential of NEDD4L function as a biomarker to predict the clinical outcome of glioma patients.